Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 1/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.45 |
| ▸ | WDR5 | P61964 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602914 | 0.90 | PTPN11 (0.56) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL6629678 | 0.85 | S1PR3 (0.65) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL6630953 | 0.85 | S1PR3 (0.65) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL6334612 | 0.83 | S1PR3 (0.64) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL8545717 | 0.81 | MAPK1 (0.52) | S1PR3MAPK1 | |
| SCHEMBL4130038 | 0.78 | S1PR3 (0.71) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL4600819 | 0.77 | PTPN11 (0.60) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL26723828 | 0.77 | PTPN11 (0.49) | S1PR3PTPN11PTPN1PTPN6 | |
| SCHEMBL4125056 | 0.77 | S1PR3 (0.78) | S1PR3PTPN11WDR5PTPN1PTPN6 | |
| SCHEMBL7029380 | 0.76 | S1PR3 (1.00) | S1PR3PTPN11WDR5PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1368352-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002074774-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | S1PR3 605/4885PTPN11 1967/4885WDR5 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.